Who can take part?
Patients with Muscle-invasive Bladder Cancer.
What is involved for you?
Patients in the trial may receive the investigational product enfortumab vedotin (EV) + pembrolizumab (pembro) or receive standard chemotherapy gemcitabine + cisplatin before having surgery to remove the bladder. Patients who are having the experimental treatment will continue to receive enfortumab vedotin (EV) + pembrolizumab (pembro) after surgery. During visits to the clinic all participants will have physical assessments, blood tests and scans to assess the status of the tumour.